Blum Holdings Inc (BLMH): TRTC Investors Advices !! To get the...

Doc.007 · 2013-09-18T10:45:01.0970000Z

TRTC Investors Advices !! To get the Shorts under control and Your Buy Orders completed in Time. Apply the following Procedure : 1. Place Buy- Orders 2 - 3 % higher than the OTC ASK to make sure your Orders get completed in Time. Regrettably need to inform the OTC Bid or Ask is not so reliable, its not NYSE or NASDAQ ! By applying this you get the Stocks at 0 - max. 1 % higher. 2. Place Sell- Orders also only at ASK, because by this the Shorts get not any Stocks at desired lower Prices and for Not Playing Into Their Hands Need To Ignoring the BID !! Keep In Mind, Shorts to Profit- Cover need Finally To Buy Cheap, Or Get Big- Losses By The Option‘s Leverage !! 3. By this also ensured, the Stock- Price more easy increasing and by this you get more than compensated for buying maybe at 0 - max. 1 % higher ! The Best Advices For Happy TRTC Investing !! ATTENTION : This Advices- System like a Snowball- Chain- Reaction is ENSURING a gradually continues Stock- Price Increase, but only if all Investors consequently applying it or at least 90 % of it !! Under these conditions to follow the ASK, automatically the BID by some delay is also Increasing when realizing to be useless ! Resulting its the world smartest System to support Stocks Profit. FINRA Original - Warns Investors of Marijuana Stock Scams by Companies Not SEC Registered - Therefore Resulting As Preferable Remains Only TRTC, CBIS, GWPH : http://www.finra.org/Newsroom/NewsReleases/2013/P325363 Herewith Invited all MJxA, ERxx, MDxX, Etc. to become Real SEC Certified TRTC Investors !! .

Play Episode

6min

Proactive - Interviews for investors

FDA approval sees Orthocell’s Remplir enter multi-billion dollar US nerve market

Orthocell Ltd chairman John van der Wielen talked with Proactive about the company receiving FDA clearance for its nerve repair product, Remplir, paving the way for entry into the multi-billion US healthcare market. The approval marks a significant milestone in Orthocell’s international growth strategy and reflects the strength of its regulatory and clinical capabilities. Van der Wielen emphasised the significance of breaking into the US market in a challenging regulatory environment. “Not many people would have thought with the current US turmoil, a company like ours could achieve FDA clearance,” he said. Orthocell has established operations in the US with logistics and distribution already in place. The company is implementing a hybrid sales model using in-house personnel and regional distributors, aiming for rapid initial uptake with an eye on more exclusive arrangements in the future. Remplir’s three-year shelf life and no temperature control requirement make it ideal for streamlined deployment. He also highlighted that Orthocell has already performed over 2,000 procedures in Australia and anticipates the US market to be 20 to 30 times larger, creating a strong revenue opportunity. With $32 million in cash reserves, the company expects to become cash flow positive within two years. 👉 For more interviews and updates, head to Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications. #Orthocell #FDAApproval #Remplir #NerveRepair #MedicalDevices #BiotechNews #USHealthcare #OrthocellRemplir #InvestorUpdate #ProactiveInvestors #SurgicalInnovation #ASX

Proactive - Interviews for investors

Nextech3D.ai disrupts industry with launch of AI-powered Ecommerce content studio

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce the launch of a new AI-powered feature as part of the company’s Ecommerce AI Studio. The platform utilizes generative AI to create photorealistic lifestyle images and videos of products—such as apparel, accessories, and furniture—being worn, held, or displayed in realistic settings, eliminating the need for traditional photography. Gappelberg highlighted that ToggleStudios, Nextech3D.ai’s AI-driven content creation tool, is designed to help online retailers generate lifestyle content at scale. The platform reduces reliance on costly and time-consuming physical photoshoots, enabling faster content production, lower operating costs, and increased visual output. The new feature will allow users to generate AI-rendered images of apparel on virtual models with varied backgrounds and appearances. Additionally, retailers can visualize accessories, electronics, and other items in realistic usage scenarios, enhancing product presentation for e-commerce. Another major upgrade is the automated generation of product videos and interactive 3D visuals. Using advanced AI, the system simulates lighting, texture, and perspective, ensuring high-quality imagery that closely replicates traditional photography—but in less time and at a lower cost. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #AmazonSellerCentral #3DModeling #AIPhotography #EcommerceInnovation #3DTechnology #LifestylePhotography #ProactiveInterviews #TechInnovation #AmazonPartners#proactiveinvestors #nextech3d.al

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Proactive - Interviews for investors

Switch Metals eyes fast-track tantalum output in Côte d'Ivoire as it lists on AIM

Switch Metals Plc (AIM:SWT) CEO Karl Akueson talked with Proactive's Stephen Gunnion about the company’s listing on London’s AIM market and its focus on developing tantalum projects in Côte d'Ivoire. Akueson explained that Switch Metals, a private company he founded, was acquired through a reverse takeover by Oneiro Energy. The company's flagship Issia project hosts tantalum mineralisation, including occurrences of coltan at surface. According to Akueson, this provides an opportunity for near-term production from shallow deposits, with the company aiming to reach output within the next two years. He described tantalum as “a very strategic technology metal… in our mobile phones, laptops, plasma TV, everything we use daily,” highlighting its importance and rarity. Akueson emphasised that 60% of the global supply currently comes from the DRC and Rwanda, and Switch Metals aims to become a significant alternative source. Discussing the decision to list in the UK, Akueson pointed to his personal background and the UK’s long-standing understanding of African production. The £2 million fundraise will support resource definition work at Issia, with plans to quickly define a resource and develop economic parameters to demonstrate value. “Tantalum is probably one of the most critical [metals], and a metal that is unique,” Akueson noted. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #Tantalum #SwitchMetals #CotedIvoireMining #CriticalMinerals #AIMListing #JuniorMining #ResourceDefinition #Coltan #TechMetals #ProactiveInvestors

Followers	31
Posts	6277
Boards Moderated	1
Alias Born	03/25/2012

Volume:	-
Day Range:
Bid:	0.08
Ask:	0.08
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

BLMH Detailed Quote

Recent BLMH News

More BLMH News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent BLMH News

Go Ad-Free